

Jian-Chuan Xia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3002488/publications.pdf>

Version: 2024-02-01

94
papers

3,354
citations

117625

34
h-index

182427

51
g-index

95
all docs

95
docs citations

95
times ranked

4972
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired bone marrow microenvironment and stem cells in transfusion-dependent beta-thalassemia. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112548.	5.6	3
2	CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 251.	6.3	20
3	CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. , 2022, 10, e004029.		44
4	Cancer-associated Fibroblast-mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression. <i>Hepatology</i> , 2021, 73, 1717-1735.	7.3	147
5	Identification of Key Genes With Differential Correlations in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 675438.	3.7	14
6	Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2091-2102.	1.4	3
7	The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. <i>Clinical and Translational Immunology</i> , 2021, 10, e1257.	3.8	4
8	Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin. <i>Cell Death and Disease</i> , 2021, 12, 1093.	6.3	9
9	Acyglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3 ^β signalling pathway in renal cell carcinoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 2.	17.0	36
10	Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1154.	3.8	12
11	Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2020, 89, 107139.	3.8	11
12	Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1521-1534.	6.4	41
13	Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. <i>Oncolmmunology</i> , 2020, 9, 1752563.	4.6	15
14	<p>The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 185-197.	2.0	5
15	Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1113.	3.8	12
16	CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 825-834.	4.2	14
17	<p>IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6691-6702.	1.9	24
18	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26

#	ARTICLE	IF	CITATIONS
19	Low-Dose IFN γ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 3737-3748.	0.9	89
20	TES functions as a Mena-dependent tumor suppressor in gastric cancer carcinogenesis and metastasis. <i>Cancer Communications</i> , 2019, 39, 1-14.	9.2	7
21	Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. <i>Oncolmmunology</i> , 2019, 8, e1528411.	4.6	16
22	PD-L1 expression patterns in tumour cells and their association with CD8 ⁺ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. <i>Journal of Cancer</i> , 2019, 10, 1154-1161.	2.5	18
23	Anti- β FR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against β FR-positive Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 284-296.	2.4	48
24	HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 76-87.	2.7	9
25	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. <i>Oncolmmunology</i> , 2018, 7, e1417721.	4.6	33
26	IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1373234.	4.6	47
27	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6457-6468.	1.9	23
28	SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 1240.	2.6	28
29	Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. <i>Journal of Cancer</i> , 2018, 9, 4204-4214.	2.5	4
30	Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort. <i>Journal of Cancer</i> , 2018, 9, 3447-3455.	2.5	11
31	Dendritic cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 2499-2511.	2.7	14
32	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2017, 6, e1312240.	4.6	68
33	Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. <i>BMC Cancer</i> , 2017, 17, 412.	2.6	24
34	Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. <i>Chinese Journal of Cancer</i> , 2017, 36, 77.	4.9	26
35	Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients. <i>Journal of Cancer</i> , 2017, 8, 606-616.	2.5	3
36	Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3812-3827.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Increased expression of protein kinase CK2 β correlates with poor patient prognosis in epithelial ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0174037.	2.5	12
38	Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 6323-6334.	1.8	21
39	The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2016, 7, 626-632.	2.5	51
40	The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 54.	4.9	7
41	Evaluation of the immunogenicity of ALDH ^{high} human head and neck squamous cell carcinoma cancer stem cells in vitro. <i>Oral Oncology</i> , 2016, 59, 30-42.	1.5	23
42	Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting. <i>Cancer Research</i> , 2016, 76, 4661-4672.	0.9	62
43	PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. <i>Oncolmunology</i> , 2016, 5, e1176653.	4.6	59
44	Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2016, 55, 64-76.	2.7	24
45	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. <i>Oncolmunology</i> , 2016, 5, e1083671.	4.6	56
46	Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 16248-16261.	1.8	28
47	IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21853-21864.	1.8	31
48	Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. <i>Oncotarget</i> , 2016, 7, 26670-26679.	1.8	51
49	A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9202.	3.3	22
50	Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 598-607.	2.7	53
51	Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. <i>Oncolmunology</i> , 2015, 4, e990767.	4.6	86
52	Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Oncolmunology</i> , 2015, 4, e976507.	4.6	61
53	Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. <i>Oncolmunology</i> , 2015, 4, e1038017.	4.6	14
54	Promise of cancer stem cell vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2796-2799.	3.3	14

#	ARTICLE	IF	CITATIONS
55	Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. <i>Stem Cells</i> , 2015, 33, 354-366.	3.2	54
56	Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0130620.	2.5	21
57	A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. <i>Oncotarget</i> , 2015, 6, 27267-27274.	1.8	9
58	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41339-41349.	1.8	79
59	Protein kinase CK2 α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 34800-34817.	1.8	46
60	Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 40920-40933.	1.8	27
61	Decreased Expression of the GATA3 Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e87195.	2.5	11
62	Reduced Expression of Uroplakin 1A Is Associated with the Poor Prognosis of Gastric Adenocarcinoma Patients. <i>PLoS ONE</i> , 2014, 9, e93073.	2.5	12
63	Characterization of a Novel Transgenic Mouse Tumor Model for Targeting HER2+ Cancer Stem Cells. <i>International Journal of Biological Sciences</i> , 2014, 10, 25-32.	6.4	12
64	The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. <i>Tumor Biology</i> , 2014, 35, 701-707.	1.8	20
65	OK432 synergizes with IFN γ to confer dendritic cells with enhanced antitumor immunity. <i>Immunology and Cell Biology</i> , 2014, 92, 263-274.	2.3	3
66	Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. <i>Medical Oncology</i> , 2014, 31, 102.	2.5	25
67	Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer. <i>Medical Oncology</i> , 2014, 31, 53.	2.5	12
68	Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3003-3011.	7.0	68
69	Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. <i>Scientific Reports</i> , 2014, 4, 5177.	3.3	93
70	The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 4305-4311.	1.5	68
71	Decreased expression of interleukin-36 α correlates with poor prognosis in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1675-1685.	4.2	35
72	Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients. <i>Journal of Immunotherapy</i> , 2013, 36, 287-293.	2.4	61

#	ARTICLE	IF	CITATIONS
73	Decreased Expression of Transcription Elongation Factor A-Like 7 Is Associated with Gastric Adenocarcinoma Prognosis. <i>PLoS ONE</i> , 2013, 8, e54671.	2.5	12
74	Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. <i>Chinese Journal of Cancer</i> , 2013, 32, 553-60.	4.9	8
75	Decreased Expression of the FOXO3a Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma Patients. <i>PLoS ONE</i> , 2013, 8, e78158.	2.5	45
76	Autologous Cytokine-induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma. <i>Journal of Immunotherapy</i> , 2012, 35, 189-195.	2.4	47
77	Involvement of hepatitis B virus X gene (HBx) integration in hepatocarcinogenesis via a recombination of HBx/Alu core sequence/subtelomeric DNA. <i>FEBS Letters</i> , 2012, 586, 3215-3221.	2.8	13
78	Decreased expression of V α 1 and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. <i>Journal of Surgical Oncology</i> , 2012, 106, 286-293.	1.7	19
79	The Prognostic Value of Tumor-Infiltrating Neutrophils in Gastric Adenocarcinoma after Resection. <i>PLoS ONE</i> , 2012, 7, e33655.	2.5	104
80	Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer. <i>PLoS ONE</i> , 2012, 7, e40364.	2.5	85
81	Poor Prognosis of Gastric Adenocarcinoma with Decreased Expression of AHRR. <i>PLoS ONE</i> , 2012, 7, e43555.	2.5	16
82	Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 544-549.	2.8	24
83	Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 771-777.	5.1	33
84	The Accumulation and Prognosis Value of Tumor Infiltrating IL-17 Producing Cells in Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2011, 6, e18219.	2.5	118
85	Reduced Expression of Transcription Factor AP-2 β Is Associated with Gastric Adenocarcinoma Prognosis. <i>PLoS ONE</i> , 2011, 6, e24897.	2.5	35
86	Identification of LZAP as a New Candidate Tumor Suppressor in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e26608.	2.5	38
87	Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. <i>Cancer Biology and Therapy</i> , 2010, 10, 368-375.	3.4	31
88	Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. <i>Cancer Biology and Therapy</i> , 2010, 9, 903-907.	3.4	39
89	Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. <i>Chinese Journal of Cancer</i> , 2010, 29, 641-648.	4.9	36
90	Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1587-1597.	4.2	38

#	ARTICLE	IF	CITATIONS
91	Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1247-1253.	2.5	149
92	Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Letters, 2008, 261, 183-192.	7.2	54
93	Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas. Journal of Immunotherapy, 2008, 31, 63-71.	2.4	150
94	Loss of heterozygosity analysis of a candidate gastric carcinoma tumor suppressor locus at 7q31. Cancer Genetics and Cytogenetics, 2006, 166, 166-172.	1.0	5